US Patent 10,220,023: Ponesimod Dosing-Regimen Claims, Patent Scope, and Generic-Entry Risk
US Patent No. 10,220,023 protects a specific initiation and re-initiation titration schedule for ponesimod, the active ingredient in Ponvory. It is a method-of-use patent, not a composition-of-matter patent. The protected regimen escalates oral once-daily dosing from 2 mg to 10 mg over 11 days, followed by either a 10-mg or 20-mg maintenance regimen for multiple sclerosis.
The patent’s commercial importance comes from the fact that its claims closely track the FDA-approved Ponvory dosing schedule. A generic applicant seeking approval for a label containing the same initiation regimen would face a substantial infringement risk during the patent term.
What drug does US Patent 10,220,023 protect?
US 10,220,023 covers ponesimod, identified in the patent claims as:
(R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one
The claimed molecule is ponesimod, an oral sphingosine-1-phosphate receptor modulator. Ponesimod selectively modulates S1P receptor activity and is used to reduce lymphocyte migration from lymphoid tissue. The FDA approved ponesimod under the brand name Ponvory for adults with relapsing forms of multiple sclerosis.[1]
| Item |
Data |
| Active ingredient |
Ponesimod |
| Brand |
Ponvory |
| Sponsor and manufacturer |
Janssen Pharmaceuticals, Inc., part of Johnson & Johnson |
| Therapeutic area |
Multiple sclerosis |
| FDA dosage form |
Oral tablets |
| Patent at issue |
US 10,220,023 |
| Patent type |
Method of treatment and dosing regimen |
| FDA approval |
March 18, 2021 |
| Approved indication |
Relapsing forms of multiple sclerosis |
| Relevant patent protection |
Initiation, re-initiation and maintenance dosing |
The patent does not claim ponesimod as a new chemical entity. Its commercial value lies in the administration sequence and dosing architecture.
What are the core claims of US 10,220,023?
The independent claim requires all of the following elements:
- Administration of ponesimod or a pharmaceutically acceptable salt.
- Administration to a human subject.
- Treatment of a disease associated with an activated immune system.
- Multiple sclerosis as the claimed disease.
- Oral administration once daily.
- An 11-day dose escalation:
- 2 mg on days 1 and 2;
- 3 mg on days 3 and 4;
- 4 mg on days 5 and 6;
- 5 mg on day 7;
- 6 mg on day 8;
- 7 mg on day 9;
- 8 mg on day 10; and
- 9 mg on day 11.
- A maintenance regimen consisting of either:
- 10 mg once daily from day 12 onward; or
- 10 mg once daily for two, three or four days, followed by 20 mg once daily.
- The regimen must occur during initial treatment or after treatment is restarted following discontinuation.
Claim 1 contains the principal protection. Claims 2 through 4 narrow the maintenance sequence. Claims 5 through 12 narrow the disease population to relapsing or relapsing-remitting multiple sclerosis.
What dosing schedules are covered?
| Claim |
Protected dosing sequence |
| Claim 1 |
2-9 mg escalation over days 1-11, then either 10 mg maintenance or 10 mg for 2-4 days followed by 20 mg |
| Claim 2 |
2-9 mg escalation, 10 mg for 2, 3 or 4 days, then 20 mg |
| Claim 3 |
2-9 mg escalation, 10 mg on days 12-14, then 20 mg from day 15 |
| Claim 4 |
2-9 mg escalation, then 10 mg from day 12 onward |
| Claims 5-6 |
Claim 1 limited to relapsing or relapsing-remitting MS |
| Claims 7-8 |
Claim 2 limited to relapsing or relapsing-remitting MS |
| Claims 9-10 |
Claim 3 limited to relapsing or relapsing-remitting MS |
| Claims 11-12 |
Claim 4 limited to relapsing or relapsing-remitting MS |
The patent therefore covers both the FDA-approved 20-mg maintenance pathway and a 10-mg maintenance pathway.
How broad is the patent’s claim scope?
The patent is chemically narrow but commercially relevant.
Chemical scope
The claims identify one specific active compound, ponesimod, or a pharmaceutically acceptable salt. They do not cover other S1P receptor modulators such as fingolimod, siponimod, ozanimod or etrasimod.
The salt language broadens the claim beyond one specific solid form or counterion. A ponesimod salt would remain within the literal scope if the other claim elements are met. The claims do not require a particular tablet formulation, excipient, coating, package or manufacturing process.
Patient-population scope
The claims focus on multiple sclerosis. Dependent claims specify relapsing MS and relapsing-remitting MS. The patent does not require a particular level of disability, prior treatment history, age, sex or biomarker status.
The phrase “disease or disorder associated with an activated immune system” appears in claim 1, but the claim then identifies multiple sclerosis as the disease. The practical scope is therefore centered on ponesimod treatment of MS rather than a broad platform claim covering all immune-mediated diseases.
Administration scope
The claims require oral once-daily administration. They do not cover:
- Intravenous ponesimod;
- Non-daily administration;
- A dose escalation that omits one of the listed doses;
- A substantially different escalation sequence;
- A regimen beginning at 10 mg or 20 mg without the claimed titration;
- Use of another S1P modulator.
The re-initiation language is important. The claims apply not only to first treatment but also to restarting therapy after discontinuation. That creates a second infringement trigger for patients who interrupt treatment and later resume therapy.
What formulations are protected by US 10,220,023?
US 10,220,023 is not primarily a formulation patent. Its claims are directed to administration of ponesimod, without requiring a specific tablet composition.
The patent can potentially read on:
- Immediate-release ponesimod tablets;
- Tablets containing ponesimod free compound;
- Tablets containing a pharmaceutically acceptable ponesimod salt;
- Blister-pack or titration-pack presentations;
- Commercial products that implement the claimed sequence.
A generic tablet could avoid formulation-specific patent claims while still infringing the dosing claims if its label directs the same 11-day escalation and maintenance regimen.
The patent does not appear, from the supplied claims, to require:
- A particular particle-size distribution;
- A specific polymorph;
- A defined dissolution profile;
- A particular excipient system;
- A fixed-release profile;
- A manufacturing process.
Those issues would normally be addressed in separate composition, formulation or process patents.
When does US Patent 10,220,023 lose exclusivity?
The patent issued on February 26, 2019. Its effective expiration is governed by the patent-term rules applicable to the earliest effective nonprovisional or international filing date, subject to any patent-term adjustment or extension.
| Event |
Date or status |
| Patent issuance |
February 26, 2019 |
| Nominal statutory term |
20 years from the applicable earliest effective filing date |
| Expected ordinary expiration window |
2033-2034, based on the patent family’s development and filing chronology |
| FDA approval of Ponvory |
March 18, 2021 |
| Patent-term extension relevance |
Potentially limited because this is a method-of-use patent and any extension must be confirmed in the USPTO and Orange Book records |
The precise enforceable expiration date should be taken from the USPTO patent record and the FDA Orange Book entry for the patent. Patent issuance date alone does not determine expiration.
The patent is separate from any new chemical entity exclusivity and from other ponesimod patents. Generic entry may therefore depend on the combined status of composition, method-of-use, formulation and dosing patents.
What is the Orange Book status of US 10,220,023?
Ponvory is an FDA-approved small-molecule product. Its relevant patent information is reported through the FDA Orange Book rather than the Purple Book, which is used primarily for licensed biological products.[2]
US 10,220,023 is commercially significant because its claimed dosing schedule corresponds to the labeled Ponvory initiation regimen. The FDA label directs:
- 2 mg on days 1 and 2;
- 3 mg on days 3 and 4;
- 4 mg on days 5 and 6;
- 5 mg on day 7;
- 6 mg on day 8;
- 7 mg on day 9;
- 8 mg on day 10;
- 9 mg on day 11; and
- 20 mg once daily beginning on day 15.[1]
That schedule maps directly to claim 3 and to the 20-mg branch of claim 1. The label therefore creates a substantial risk that a product approved with the same dosing instructions would practice the claimed method.
A complete generic-entry analysis must distinguish between:
- Patents listed for the approved product;
- FDA use codes attached to method-of-use listings;
- Patent expiration dates;
- Any pediatric exclusivity;
- Any patent-term extension;
- Whether a generic applicant can carve out the patented indication or dosing instruction.
What Paragraph IV challenges could affect ponesimod generic entry?
A generic applicant could challenge US 10,220,023 through an ANDA Paragraph IV certification, asserting that the patent is invalid, unenforceable or not infringed.[3]
The principal potential theories would include:
Noninfringement
A generic applicant could argue that its proposed label does not direct the claimed schedule. Possible design-around positions could involve:
- Omitting the patented initiation instructions from the label;
- Using a different titration schedule;
- Seeking approval for a carved-out indication;
- Providing ponesimod only for a use that does not require the patented regimen.
The strength of this strategy depends on FDA labeling requirements. If the approved ponesimod regimen is medically necessary for safe initiation, a label carve-out could be difficult to implement without undermining the product’s practical use.
Invalidity
Potential invalidity arguments would focus on:
- Anticipation by prior clinical protocols;
- Obviousness based on known S1P-modulator titration strategies;
- Lack of written description for the full claimed schedule;
- Lack of enablement for the claimed patient populations and dosing branches;
- Indefiniteness in terms such as “re-initiation” or “after drug discontinuation.”
The most important validity issue is likely obviousness. Dose-escalation regimens are vulnerable when prior art identifies the same active compound, the same safety concern and predictable dose increases. The patent holder would counter that the particular sequence and duration produced an unexpected safety or tolerability profile.
Enforceability and statutory safe-harbor issues
An ANDA applicant generally benefits from the Hatch-Waxman litigation framework, including the statutory safe harbor for activities reasonably related to FDA submission.[3] Commercial marketing after approval would remain subject to method-of-use infringement risk unless the patent expires, is held invalid or is avoided through an effective label carve-out.
Which companies are challenging US 10,220,023?
The patent is associated with the Ponvory product franchise, which is commercialized by Janssen. The supplied record does not identify a Paragraph IV notice, ANDA litigation case, settlement agreement or license involving a generic challenger.
A patent number alone does not establish that a challenge has been filed. Such events would ordinarily appear in federal district-court dockets, FDA patent-challenge records or company disclosures.
No biosimilar challenge applies because ponesimod is a chemically synthesized small molecule, not a biologic. A competing ponesimod product would proceed through the ANDA pathway, not the biosimilar pathway.
What litigation and settlement issues affect this patent?
The key litigation question is whether the patent is asserted against a generic applicant whose proposed label includes the Ponvory titration schedule.
| Litigation issue |
Commercial impact |
| Claim construction |
Determines whether the proposed titration and restart instructions fall within the claims |
| Induced infringement |
May expose a generic sponsor if its label encourages doctors or patients to follow the patented schedule |
| Label carve-out |
Could reduce infringement risk but may limit the approved product’s clinical utility |
| Obviousness |
Main validity risk for a regimen patent |
| Written description |
Relevant to the breadth of the claimed 10-mg and 20-mg maintenance alternatives |
| Settlement |
Could delay generic launch through a negotiated entry date or license |
| Regulatory stay |
A timely Paragraph IV suit can trigger the Hatch-Waxman 30-month stay, subject to statutory exceptions |
No settlement terms can be inferred from the patent claims. A settlement would require a separate agreement or court record.
How does the patent compare with competing multiple-sclerosis drug patents?
US 10,220,023 has a narrower scope than a composition-of-matter patent but a closer relationship to the approved label.
| Patent category |
Typical protection |
Relevance to ponesimod |
| Composition patent |
The active molecule itself |
Can block all uses and formulations during its term |
| Salt or polymorph patent |
Specific solid forms or salts |
Can block particular commercial presentations |
| Formulation patent |
Tablet, capsule, excipient or release system |
May be avoided through formulation changes |
| Method-of-use patent |
Treatment of a disease |
Depends on the label and actual use |
| Dosing-regimen patent |
Specific dose sequence and maintenance schedule |
Closely aligned with the Ponvory label |
| Manufacturing patent |
Chemical synthesis or purification |
May create supply-chain or process risk |
Ponesimod competes clinically with other oral MS therapies, including fingolimod, siponimod, ozanimod and dimethyl fumarate. Those products have separate patent estates. Their patents do not ordinarily read on ponesimod because US 10,220,023 requires the specific ponesimod molecule and dosing sequence.
How strong is the patent estate for ponesimod?
The dosing patent is commercially meaningful but litigation-sensitive.
Strength factors
- The claimed schedule is highly specific.
- The schedule tracks the FDA-approved label.
- The claims cover both treatment initiation and re-initiation.
- The claims include the clinically important 20-mg maintenance dose.
- Dependent claims target the commercially relevant relapsing-remitting MS population.
- A generic label using the same schedule would create a direct infringement theory.
Weakness factors
- The patent does not protect the molecule itself.
- The claims may be vulnerable to obviousness attacks based on prior S1P-modulator titration practices.
- A generic applicant may attempt a label carve-out.
- Method claims depend heavily on prescriber and patient conduct.
- The claims do not independently block alternative formulations or manufacturing routes.
- The patent’s commercial blocking power depends on the status of other ponesimod patents.
What generic launch scenarios exist?
Scenario 1: Full-label generic launch after patent expiration
A generic applicant markets ponesimod with the full initiation and maintenance schedule after expiration or successful invalidation of the relevant patent estate. This is the lowest litigation-risk pathway.
Scenario 2: Paragraph IV litigation
The applicant certifies that US 10,220,023 is invalid, unenforceable or not infringed. Janssen sues. FDA approval may be delayed under the Hatch-Waxman litigation framework.
Scenario 3: Label carve-out
The applicant removes the patented dosing instruction or indication from its label. This strategy faces practical constraints if the titration schedule is central to safe use and appears necessary for the approved product.
Scenario 4: Alternative dosing regimen
The applicant proposes a materially different regimen. This could reduce literal infringement risk, but the FDA may not approve an alternative regimen without supporting clinical and safety data.
What geographic coverage does US 10,220,023 provide?
The patent provides rights only in the United States. Corresponding foreign applications may exist in the ponesimod patent family, but a US patent does not establish protection in Europe, Japan, Canada, China or other jurisdictions.
International freedom-to-operate analysis should separately review:
- European Patent Office family members;
- United Kingdom national rights;
- Canadian rights;
- Japanese rights;
- Chinese rights;
- Patent-term adjustments and supplementary protection certificates;
- National litigation and opposition proceedings.
A generic company could face different entry dates by country because prosecution outcomes, patent-term rules and regulatory exclusivity periods vary.
Key Takeaways
- US 10,220,023 is a ponesimod dosing-regimen patent.
- It protects an 11-day oral once-daily escalation from 2 mg to 9 mg.
- The patent covers either 10 mg maintenance or escalation to 20 mg maintenance.
- Claims 3 and 4 are the most commercially direct: claim 3 tracks the FDA-approved 20-mg regimen, while claim 4 covers 10-mg maintenance.
- The patent applies to initiation and re-initiation after discontinuation.
- Dependent claims focus on relapsing and relapsing-remitting multiple sclerosis.
- The patent does not claim ponesimod as a molecule, a specific tablet formulation or a manufacturing process.
- Generic products would likely face infringement risk if their labels reproduce the Ponvory titration schedule.
- Ponesimod is a small molecule, so biosimilar litigation does not apply.
- Generic entry depends on the combined status of ponesimod composition, formulation, method-of-use and dosing patents, not US 10,220,023 alone.
- The patent’s nominal term extends into the 2033-2034 period, subject to the official USPTO and FDA records for the exact expiration date and any term adjustment.
FAQs About US Patent 10,220,023
Does US 10,220,023 cover all ponesimod products?
No. It covers ponesimod when administered according to the claimed initiation, re-initiation and maintenance schedules for multiple sclerosis. It does not broadly claim every ponesimod formulation or use.
Does stopping ponesimod and restarting it implicate the patent?
Yes. The claims expressly cover re-initiation after drug discontinuation, provided the claimed escalation sequence is used.
Is the 20-mg ponesimod maintenance dose separately protected?
Yes. Claim 3 specifically covers escalation through 10 mg on days 12, 13 and 14, followed by 20 mg from day 15 onward.
Can a generic ponesimod manufacturer avoid the patent by changing the tablet formulation?
Not necessarily. A formulation change may avoid a formulation patent, but it does not avoid a dosing-regimen claim if the product is still administered according to the patented schedule.
Does US 10,220,023 block ponesimod use outside multiple sclerosis?
The supplied claims are directed to multiple sclerosis. They do not establish broad protection for every immune-mediated disease or every non-MS use of ponesimod.
References
- U.S. Food and Drug Administration. (2021). Ponvory (ponesimod) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and supplements under GDUFA. https://www.fda.gov/drugs/guidance-compliance-regulatory-information
- United States Patent and Trademark Office. (2019). U.S. Patent No. 10,220,023. https://patents.google.com/patent/US10220023B2/en
